PTGS2 and rheumatoid arthritis: Lumiracoxib 164 (Scheme 60) belongs to the class of nonsteroidal anti-inflammatorydrugs (NSAIDs)and has excellent cyclooxygenase 2 (COX-2) selectivity.289 It was patented in 1997, approved for medicaluse in 2003, and was marketed by Novartis under the trade name Prexige for the treatment of inflammatory effects of osteoarthritisand rheumatoid arthritis.290